Society of Behavioral Medicine supports implementation of high quality lung cancer screening in high-risk populations

Karriem S. Watson, Amanda C. Blok, Joanna Buscemi, Yamile Molina, Marian Fitzgibbon, Melissa A. Simon, Lance Williams, Kameron Matthews, Jamie L. Studts, Sarah E. Lillie, Jamie S. Ostroff, Lisa Carter-Harris, Robert A. Winn

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The Society of Behavioral Medicine (SBM) supports the United States Preventive Services Task Force (USPSTF) recommendation of low-dose computed tomography (LDCT) screening of the chest for eligible populations to reduce lung cancer mortality. Consistent with efforts to translate research findings into real-world settings, SBM encourages health-care providers and health-care systems to (1) integrate evidence-based tobacco treatment as an essential component of LDCT-based lung cancer screening, (2) examine the structural barriers that may impact screening uptake, and (3) incorporate shared decision-making as a clinical platform to facilitate consultations and engagement with individuals at high risk for lung cancer about the potential benefits and harms associated with participation in a lung cancer screening program. We advise policy makers and legislators to support screening in high-risk populations by continuing to (1) expand access to high quality LDCT-based screening among underserved high-risk populations, (2) enhance cost-effectiveness by integrating evidence-based tobacco treatments into screening in high-risk populations, and (3) increase funding for research that explores implementation science and increased public awareness and access of diverse populations to participate in clinical and translational research.

Original languageEnglish (US)
Pages (from-to)669-671
Number of pages3
JournalTranslational Behavioral Medicine
Volume6
Issue number4
DOIs
StatePublished - Dec 1 2016

Fingerprint

Early Detection of Cancer
Lung Neoplasms
Population
Tomography
Tobacco
Behavioral Medicine
Translational Medical Research
Advisory Committees
Administrative Personnel
Research
Health Personnel
Cost-Benefit Analysis
Decision Making
Thorax
Referral and Consultation
Delivery of Health Care
Mortality
Therapeutics

Keywords

  • Lung cancer
  • Policy
  • Screening
  • Shared decision-making

ASJC Scopus subject areas

  • Applied Psychology
  • Behavioral Neuroscience

Cite this

Society of Behavioral Medicine supports implementation of high quality lung cancer screening in high-risk populations. / Watson, Karriem S.; Blok, Amanda C.; Buscemi, Joanna; Molina, Yamile; Fitzgibbon, Marian; Simon, Melissa A.; Williams, Lance; Matthews, Kameron; Studts, Jamie L.; Lillie, Sarah E.; Ostroff, Jamie S.; Carter-Harris, Lisa; Winn, Robert A.

In: Translational Behavioral Medicine, Vol. 6, No. 4, 01.12.2016, p. 669-671.

Research output: Contribution to journalArticle

Watson, KS, Blok, AC, Buscemi, J, Molina, Y, Fitzgibbon, M, Simon, MA, Williams, L, Matthews, K, Studts, JL, Lillie, SE, Ostroff, JS, Carter-Harris, L & Winn, RA 2016, 'Society of Behavioral Medicine supports implementation of high quality lung cancer screening in high-risk populations', Translational Behavioral Medicine, vol. 6, no. 4, pp. 669-671. https://doi.org/10.1007/s13142-016-0440-6
Watson, Karriem S. ; Blok, Amanda C. ; Buscemi, Joanna ; Molina, Yamile ; Fitzgibbon, Marian ; Simon, Melissa A. ; Williams, Lance ; Matthews, Kameron ; Studts, Jamie L. ; Lillie, Sarah E. ; Ostroff, Jamie S. ; Carter-Harris, Lisa ; Winn, Robert A. / Society of Behavioral Medicine supports implementation of high quality lung cancer screening in high-risk populations. In: Translational Behavioral Medicine. 2016 ; Vol. 6, No. 4. pp. 669-671.
@article{e6c00fb072b0413885ec9af3b8007963,
title = "Society of Behavioral Medicine supports implementation of high quality lung cancer screening in high-risk populations",
abstract = "The Society of Behavioral Medicine (SBM) supports the United States Preventive Services Task Force (USPSTF) recommendation of low-dose computed tomography (LDCT) screening of the chest for eligible populations to reduce lung cancer mortality. Consistent with efforts to translate research findings into real-world settings, SBM encourages health-care providers and health-care systems to (1) integrate evidence-based tobacco treatment as an essential component of LDCT-based lung cancer screening, (2) examine the structural barriers that may impact screening uptake, and (3) incorporate shared decision-making as a clinical platform to facilitate consultations and engagement with individuals at high risk for lung cancer about the potential benefits and harms associated with participation in a lung cancer screening program. We advise policy makers and legislators to support screening in high-risk populations by continuing to (1) expand access to high quality LDCT-based screening among underserved high-risk populations, (2) enhance cost-effectiveness by integrating evidence-based tobacco treatments into screening in high-risk populations, and (3) increase funding for research that explores implementation science and increased public awareness and access of diverse populations to participate in clinical and translational research.",
keywords = "Lung cancer, Policy, Screening, Shared decision-making",
author = "Watson, {Karriem S.} and Blok, {Amanda C.} and Joanna Buscemi and Yamile Molina and Marian Fitzgibbon and Simon, {Melissa A.} and Lance Williams and Kameron Matthews and Studts, {Jamie L.} and Lillie, {Sarah E.} and Ostroff, {Jamie S.} and Lisa Carter-Harris and Winn, {Robert A.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s13142-016-0440-6",
language = "English (US)",
volume = "6",
pages = "669--671",
journal = "Translational Behavioral Medicine",
issn = "1869-6716",
publisher = "Springer Publishing Company",
number = "4",

}

TY - JOUR

T1 - Society of Behavioral Medicine supports implementation of high quality lung cancer screening in high-risk populations

AU - Watson, Karriem S.

AU - Blok, Amanda C.

AU - Buscemi, Joanna

AU - Molina, Yamile

AU - Fitzgibbon, Marian

AU - Simon, Melissa A.

AU - Williams, Lance

AU - Matthews, Kameron

AU - Studts, Jamie L.

AU - Lillie, Sarah E.

AU - Ostroff, Jamie S.

AU - Carter-Harris, Lisa

AU - Winn, Robert A.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The Society of Behavioral Medicine (SBM) supports the United States Preventive Services Task Force (USPSTF) recommendation of low-dose computed tomography (LDCT) screening of the chest for eligible populations to reduce lung cancer mortality. Consistent with efforts to translate research findings into real-world settings, SBM encourages health-care providers and health-care systems to (1) integrate evidence-based tobacco treatment as an essential component of LDCT-based lung cancer screening, (2) examine the structural barriers that may impact screening uptake, and (3) incorporate shared decision-making as a clinical platform to facilitate consultations and engagement with individuals at high risk for lung cancer about the potential benefits and harms associated with participation in a lung cancer screening program. We advise policy makers and legislators to support screening in high-risk populations by continuing to (1) expand access to high quality LDCT-based screening among underserved high-risk populations, (2) enhance cost-effectiveness by integrating evidence-based tobacco treatments into screening in high-risk populations, and (3) increase funding for research that explores implementation science and increased public awareness and access of diverse populations to participate in clinical and translational research.

AB - The Society of Behavioral Medicine (SBM) supports the United States Preventive Services Task Force (USPSTF) recommendation of low-dose computed tomography (LDCT) screening of the chest for eligible populations to reduce lung cancer mortality. Consistent with efforts to translate research findings into real-world settings, SBM encourages health-care providers and health-care systems to (1) integrate evidence-based tobacco treatment as an essential component of LDCT-based lung cancer screening, (2) examine the structural barriers that may impact screening uptake, and (3) incorporate shared decision-making as a clinical platform to facilitate consultations and engagement with individuals at high risk for lung cancer about the potential benefits and harms associated with participation in a lung cancer screening program. We advise policy makers and legislators to support screening in high-risk populations by continuing to (1) expand access to high quality LDCT-based screening among underserved high-risk populations, (2) enhance cost-effectiveness by integrating evidence-based tobacco treatments into screening in high-risk populations, and (3) increase funding for research that explores implementation science and increased public awareness and access of diverse populations to participate in clinical and translational research.

KW - Lung cancer

KW - Policy

KW - Screening

KW - Shared decision-making

UR - http://www.scopus.com/inward/record.url?scp=84995766813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995766813&partnerID=8YFLogxK

U2 - 10.1007/s13142-016-0440-6

DO - 10.1007/s13142-016-0440-6

M3 - Article

VL - 6

SP - 669

EP - 671

JO - Translational Behavioral Medicine

JF - Translational Behavioral Medicine

SN - 1869-6716

IS - 4

ER -